4-oxo-piperidine-1-carboxylic acid methylamide | 1011470-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-oxo-piperidine-1-carboxylic acid methylamide
• 英文别名: n-Methyl-4-oxo-1-piperidinecarboxamide；N-methyl-4-oxopiperidine-1-carboxamide
• CAS: 1011470-65-7
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.184
• InChiKey: HGXMGQNSASZWCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-oxo-piperidine-1-carboxylic acid methylamide 、 isobu-diol 在 对甲苯磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以76%的产率得到N-methyl-3,3-bis[[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]methyl]-1,4-dioxa-8-azaspiro[4.5]decane-8-carboxamide
  参考文献：
  名称：

  Malaria-Infected Mice Are Cured by Oral Administration of New Artemisinin Derivatives

  摘要：

  In four or five chemical steps from the 1,2,4-trioxane artemisinin, a new series of 23 trioxane dimers has been prepared. Eleven of these new trioxane dimers cure malaria-infected mice via oral dosing at 3 x 30 mg/kg. The clinically used trioxane drug sodium artesunate prolonged mouse average survival to 7.2 days with this oral dose regimen. In comparison, animals receiving no drug die typically on day 6-7 postinfection. At only 3 x 10 mg/kg oral dosing, seven dimers prolong the lifetime of malaria-infected mice to days 14-17, more than double the chemotherapeutic effect of sodium artesunate. Ten new trioxane dimers at only a single oral dose of 30 mg/kg prolong mouse average survival to days 8.7-13.7, and this effect is comparable to that of the fully synthetic trioxolane drug development candidate OZ277, which is in phase 11 clinical trials.

  DOI：

  10.1021/jm701168h
• 作为产物：
  描述：

  甲胺 、 伊立替康杂质7 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 以45%的产率得到4-oxo-piperidine-1-carboxylic acid methylamide
  参考文献：
  名称：

  Malaria-Infected Mice Are Cured by Oral Administration of New Artemisinin Derivatives

  摘要：

  In four or five chemical steps from the 1,2,4-trioxane artemisinin, a new series of 23 trioxane dimers has been prepared. Eleven of these new trioxane dimers cure malaria-infected mice via oral dosing at 3 x 30 mg/kg. The clinically used trioxane drug sodium artesunate prolonged mouse average survival to 7.2 days with this oral dose regimen. In comparison, animals receiving no drug die typically on day 6-7 postinfection. At only 3 x 10 mg/kg oral dosing, seven dimers prolong the lifetime of malaria-infected mice to days 14-17, more than double the chemotherapeutic effect of sodium artesunate. Ten new trioxane dimers at only a single oral dose of 30 mg/kg prolong mouse average survival to days 8.7-13.7, and this effect is comparable to that of the fully synthetic trioxolane drug development candidate OZ277, which is in phase 11 clinical trials.

  DOI：

  10.1021/jm701168h